Microfluidic reveals generation of platelet-strings on tumoractivated endothelium

Summary

Neoplastic diseases are often associated with thromboembolic events,however the precise mechanism underlying this observation is a matter of ongoing investigation. It is known that matrixmetalloproteinase- 1 (MMP-1) canonically activates the thrombin receptor (PAR-1) and we recently reported that highly metastatic tumor cells of melanoma and colon cancer are secreting matrixmetalloproteinase-1. This tumor-derived MMP1 was shown to be a major activator of endothelial PAR-1, thus leading to endothelial cell activation. As tumor-induced thrombosis is a characteristic of metastazing tumors, we investigated whether tumor-derived supernatant (TUSN) from melanoma and colon cancer may induce adhesion of circulating platelets,an initial step in thrombus formation.A time-course study revealed that TU-SN induces a rapid secretion of von Willebrand factor (VWF) within minutes. Using a novel microfluidic device we analyzed platelet-endothelial interactions in a closed circuit. Immunofluorescence imaging showed that TU-SN rapidly induces platelet- string formation via secreted VWF. We demonstrated that tumor-derived supernatant is a potent agonist inducing platelet adhesion under flow conditions.

Keywords

von Willebrand factor - platelet physiology - cancer - imaging

• References

• 1 Trousseau A. Phlegasia alba dolens. Clinique Medicale del’Hotel-Dieu de Paris London: The New Sydenham Society 1865; 3: 94-99.
• 2 Nand S, Fisher SG, Salgia R. et al. Hemostatic abnormalities in untreated cancer: incidence and correlationwith thrombotic and hemorrhagic complications. J Clin Oncol 1987; 5: 1998-2003.
• 3 Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost 1978; 5: 1-26.
• 4 De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50: 187-196.
• 5 Dvorak HF, Quay SC, Orenstein NS. et al. Tumor shedding and coagulation. Science 1981; 212: 923-924.
• 6 Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137.
• 7 Boire A, Covic L, Agarwal A. et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120: 303-313.
• 8 Goerge T, Barg A, Schnaeker EM. et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 2006; 66: 7766-7774.
• 9 Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1: 1335-1342.
• 10 Dong JF, Moake JL, Nolasco L. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
• 11 Chauhan AK, Goerge T, Schneider SW. et al. Formation of platelet strings and microthrombi in the presence of ADAMTS13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost 2007; 5: 583-589.
• 12 Barg A, Ossig R, Goerge T. et al. Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network. Thromb Haemost 2007; 97: 514-526.
• 13 Sritharan K, Strobl CJ, Schneider MF. et al. Acoustic mixing at low Reynold’s numbers. Appl Phys Lett 2006; 88: 054102.
• 14 Jurk K, Jahn UR, Van AH. et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004; 91: 334-344.